Immunotherapy of Head and Neck Cancer: Current and Future Considerations
Table 2
Monoclonal antibodies (excluding anti-EGFR agents) in clinical development in head and neck cancer [40].
Agent
Phase
Status
Study Type
Description
Bevacizumab
Clinicaltrials.gov search retrieves records for 3 phase 1 trials2 phase 1/2 trials 11 phase 2 trials 1 phase 3 trial
The phase 1, 1/2, and 2 trials are completed or ongoingThe phase 3 trial is recruiting
Several
The early-phase trials are exploring several different regimensThe phase 3 trial is a multicenter, randomized, controlled trial in which patients with recurrent or metastatic HNSCC receive chemotherapy bevacizumab. Chemotherapy consists of cisplatin, docetaxel, and fluorouracil.
anti-CD45 MAb
1 (NCT00608257)
Completed()
Dose-escalation study
Patients with EBV-positive nasopharyngeal cancer receive autologous EBV-specific cytotoxic T cells in combination with anti-CD45 MAb
MN-14 (anti-CEA MAb)
1/2 (NCT00004048)
Active, not recruiting()
Dose-escalation study
Patients with medullary thyroid cancer undergo radioimmunotherapy with MN-14 alone or combined with doxorubicin and peripheral blood stem cell rescue
CEA: carcinoembryonic antigen; EBV: Epstein-Barr virus; HNSCC: head and neck squamous cell carcinoma; MAb: monoclonal antibody.
